Skip to main content
. 2014 Apr 11;35(31):2083–2093. doi: 10.1093/eurheartj/ehu160

Table 2.

Efficacy and safety outcomes in patients with NSTE-ACS

Ticagrelor % (n) Clopidogrel % (n) HR (95% CI) P-value
Efficacy endpoints
 CV death/MI (excluding silent)/stroke 10.0 (533) 12.3 (630) 0.83 (0.74, 0.93) 0.0013
 All-cause death/MI(excl. silent)/stroke 10.5 (557) 13.0 (664) 0.82 (0.73, 0.92) 0.0006
 CV death/MI(all)/stroke/severe recurrent ischaemia/recurrent ischaemia/TIA/arterial thrombotic event 15.5 (824) 17.8 (918) 0.88 (0.80, 0.96) 0.0058
 Myocardial infarction (excluding silent) 6.6 (345) 7.7 (392) 0.86 (0.74, 0.99) 0.0419
 Cardiovascular death (includes vascular and unknown deaths) 3.7 (194) 4.9 (247) 0.77 (0.64, 0.93) 0.0070
 Stroke 1.3 (69) 1.4 (71) 0.95 (0.69, 1.33) 0.79
 All-cause death 4.3 (224) 5.8 (290) 0.76 (0.64, 0.90) 0.0020
Safety endpoints
 Major bleeding (study criteria) 13.4 (660) 12.6 (618) 1.07 (0.95, 1.19) 0.26
 Major or minor bleeding (study criteria) 18.2 (900) 16.3 (794) 1.14 (1.03, 1.25) 0.0078
 Non-CABG related major bleeding (study criteria) 4.8 (225) 3.8 (176) 1.28 (1.05, 1.56) 0.0139
 Fatal bleeding 0.3 (13) 0.4 (18) 0.72 (0.35, 1.47) 0.37
 Life threatening or fatal bleeding (study criteria) 6.6 (331) 6.5 (315) 1.05 (0.90, 1.22) 0.56
 Intracranial bleeding 0.3 (14) 0.2 (7) 2.01 (0.81, 4.99) 0.13
 Other major bleeding 7.2 (344) 6.6 (318) 1.08 (0.93, 1.25) 0.34
 Major bleeding (TIMI criteria) 9.2 (452) 8.7 (422) 1.07 (0.94, 1.22) 0.33
 Major or minor bleeding (TIMI criteria) 13.2 (653) 12.3 (602) 1.08 (0.97, 1.21) 0.16
 Non-CABG related major bleeding (TIMI criteria) 2.9 (137) 2.2 (99) 1.39 (1.07, 1.80) 0.0131
 GUSTO severe bleeding 3.1 (146) 3.2 (151) 0.96 (0.77, 1.21) 0.74
 GUSTO moderate or severe bleeding 8.6 (416) 7.8 (382) 1.08 (0.94, 1.25) 0.25

Each treatment group is summarized as Kaplan–Meier rates at 360 days and total number of events during the study. P-values and hazard ratios (95% CI) come from unadjusted Cox models testing ticagrelor vs. clopidogrel.